MOTS-c vs Sermorelin
Head-to-head comparison of MOTS-c and Sermorelin for research applications. Both peptides are studied for Anti-Aging, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Mots C | Sermorelin |
|---|---|---|
| Category | Metabolic / Mitochondrial | Growth Hormone Secretagogue |
| Mechanism | MOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. |
| Evidence Rating | D — Preclinical | C — Phase I–II Clinical Trials |
| Clinical Status | Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only) | Previously FDA-approved (Geref, discontinued); now used off-label via compounding |
| Safety Profile | No adverse effects reported in preclinical animal studies; Human tolerability is completely unknown for native MOTS-c (no completed human trials) | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 5–10 mg SC per injection | 100–300 mcg/day SC |
| Frequency | Once daily or 3–5x weekly | Once daily (typically before bed) |
| Molecular Weight | ~2174.6 g/mol | ~3357.9 g/mol |
| Half-Life | Several hours; tissue effects may persist longer | ~10–20 minutes |
Overview
MOTS-c and Sermorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
MOTS-c — Mechanism & Evidence
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.
Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.
BPC-157 5mg
5mg
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
MOTS-c is also researched for: Metabolic Health.
Sermorelin is also researched for: Body Composition, Sleep.
Safety Considerations
MOTS-c: No adverse effects reported in preclinical animal studies Human tolerability is completely unknown for native MOTS-c (no completed human trials) Modified analog CB4211 showed good tolerability in Phase 1
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
MOTS-c Half-Life: What Studies Show and What Remains Unknown
This reference clarifies what primary studies have established about MOTS-c half-life and stability, and identifies the pharmacokinetic questions that remain unanswered in humans.
MOTS-C and Metabolism: How Does MOTS-C Improve Endurance and Bone Strength?
Explore the preclinical science behind MOTS-C, a mitochondrial peptide investigated for its effects on metabolism, endurance, and bone strength.
CJC-1295 vs Sermorelin: Comparing Growth Hormone-Releasing Peptides
Compare CJC-1295 vs Sermorelin for growth hormone release. Analyze mechanisms, preclinical data, and research limitations for these GHRH analogs.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe